tiprankstipranks
Advertisement
Advertisement
AbSci: Buy Rating Backed by Proprietary Wet‑Lab Data Moat and Emerging Validation of AI‑Enabled Biologic Design
PremiumRatingsAbSci: Buy Rating Backed by Proprietary Wet‑Lab Data Moat and Emerging Validation of AI‑Enabled Biologic Design
2M ago
Absci price target raised to $10 from $4.10 at Morgan Stanley
Premium
The Fly
Absci price target raised to $10 from $4.10 at Morgan Stanley
2M ago
Absci: Clean Phase 1 Data, Strengthened ABS-201 Outlook Drive Price Target Increase from $9 to $13 and Buy Rating
Premium
Ratings
Absci: Clean Phase 1 Data, Strengthened ABS-201 Outlook Drive Price Target Increase from $9 to $13 and Buy Rating
2M ago
Absci prices 13.5M shares at $7.41 in public offering
PremiumThe FlyAbsci prices 13.5M shares at $7.41 in public offering
2M ago
Absci reports Phase 1 data from human trial of ABS-201
Premium
The Fly
Absci reports Phase 1 data from human trial of ABS-201
2M ago
Absci price target raised to $15 from $10 at Guggenheim
Premium
The Fly
Absci price target raised to $15 from $10 at Guggenheim
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100